Nichol Ochsner | executive |
Neil McFarlane | executive |
R. Clifton | executive |
Tim Lugo | analyst |
Joshua Schafer | executive |
Jonathan Aschoff | analyst |
Louise Chen | analyst |
Adrian Quartel | executive |
Oren Livnat | analyst |
Sumant Kulkarni | analyst |
Good morning, everyone. Thank you for joining the Zevra Therapeutics First Quarter 2024 Corporate Updates and Financial Results Call. Today's call is being recorded and will be made available on the company's website following the conclusion of the call. With that, I will now turn the call over to Nichol Ochsner, Vice President of Investor Relations and Corporate Communications at Zevra Therapeutics.
Good morning, and thank you for joining us today to review Zevra Therapeutic's progress in the first quarter of 2024 outlining out clinical advances, operational achievements, and financial results.